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Introduction
In the pharmaceutical industry the most exciting aspect
of Research & Development is the discovery of a new
chemical entity with one or more unique therapeutic
properties that are generally recognized and accepted as
an advance in safe and effective treatment ofdisease. The
discovery and transformation of this compound into a
product which submitted to the authorities can take up to
10 years, costing millions of dollars.
It is the mission of the pharmaceutical development
divisions to provide a stable dosage form(s) for evaluation
in clinical trials and, ultimately, a competitive market
image which can be manufactured at large scale, with
reproducible purity and quality and a shelf-life consistent
with worldwide environmental conditions. Therefore,
analytical testing in R&D laboratories, using stability
indicating methods, plays a pivotal role in many of the
decisions which lead to the ultimate definition of ’a final
product’.
The most time-consuming analyses that occur in analyti-
cal R&D laboratories are those associated with stability
testing. The minimum requirement is that three batches
of the product be manufactured, representative of the
commercial manufacturing process, equipment and
scale. These are then packaged in each type and size of
container which will be used in the market-place. For
example, for a tablet dosage form, this might be glass and
polyethylene bottles and blisters. All of these are then
placed at stability stations, simulating worldwide envir-
onmental limits to which the product will be exposed and
analytically tested at fixed intervals over a period ofup to
three to five years. In addition, the samples are subjected
to additional tegting at conditions which are more
stressful with the hope that one might project, kinetically,
changes which could highlight a stability problem early
in the stability protocol. A typical stability protocol for a
single dose of a solid dosage form translates into 648
determinations in the first year exclusive of analytical
reference standards which must be used in calculations.
When this is multiplied by the number of dosage
strengths for which a product is developed, a single
stability protocol can easily effect close to 2000 determi-
nations in the first year of testing. In 1991 the author’s
Analytical Reseach & Development Laboratories gener-
ated more than 225 000 analytical determinations, utiliz-
ing the efforts of89 bench chemists. This translated into
approximately 11"5 completed deteminations per
chemist/day. With numbers of this magnitude, one can
appreciate the role for automation and laboratory
efficiency with minimal chance for error (see figures and
2).
Laboratory automation
Laboratory automation is ’Efficiency’, is ’Computers’.
Prior to the 1970s, chromatographic methods were
conducted manually. Generally, procedures consisted of:
weighings, extractions, dilutions, filtering and/or cen-
trifugation, injections and manually determined
measurements of chromatographic peak heights and
calculations. All raw data were hand-transcribed into
Three batches
Representative of commercial process/scale/
equipment
Packaged:
All types/sizes of marketed containers
Stability stations:
25 and 30 C/60% RH
Refrigeration
Accelerated conditions:
Light (500 ft Cand)
40 C/80% RH
50C
Testing intervals:
Three month intervals/first year
Six month intervals/thereafter
Analytical testing:
Stability indicating assay
Content uniformity (initial only)
Dissolution (solid dosage forms)
Decomposition products
Figure 1. General stability requirements.
Three batches/three packages nine samples
Initial assay/three months/six months/12months five
intervals
Four tests conducted intially/three thereafter
Taken into account: complete testing not conducted at
every condition
Result: 324 samples tested
648 determinations conducted (duplicate
testing)
Note: Standards not included
This paper was read at the International Symposium on Laboratory
Automation and Robotics (October 1992, Boston, USA).
Figure 2. Typical stability protocol for one product dose:
number of determinations.
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notebooks, along with strip chart recordings. For a
typical gas chromatographic analysis of a two-compo-
nent, tablet dosage form, a chemist might complete five
samples per day. In the 1970s, efficient autoinjectors and
autosamplers came on the scene, together with early
versions of ’LAS’ (Laboratory Automation Systems).
These inroads effected computerized area integration and
calculations, while providing hard-copy records of calcu-
lated results of laboratory notebooks. With these inno-
vations, a chemist could now complete in the region of 10
samples in one and one halfdays. Robotics were added to
the laboratory ’arsenal’, in the 1980s which freed the
chemist from many time consuming manipulations and
allowed these operations to be carried out ’off-hours’.
LAS systems were more sophisticated, allowing baseline
assessment and more reliable raw data files for records
and audits. Today, it is possible for a chemist to generate
twice the workload in half the time required in the past
(See figures 3-5).
In the author’s research analytical laboratory, the
opportunities to be innovative in automation require a
careful assessment ofthe principle day-to-day laboratory
operations. These can change from time to time. While
Pre 1970s
Manual weighing
Manual liquid/liquid and/or liquid/solid extraction
Manual dilution
Manual centrifugation
Manual syringe injection
Manual peak height calculations
Raw data manually recorded in notebooks
Result: one chemist- five samples per day
Figure 3. Evolution ofa typical gas chromatographic assay: two
components in a single tablet.
1970s
Manual weighing
Manual liquid/liquid and/or liquid/solid extraction
Manual dilution
Manual centrifugation
Automated injectors
Integration of areas (early versions of LAS)
Printed data files for notebook entry
Result: one chemist- 10 samples in 1-} days
Figure 4. Evolution ofa typical gas chromatographic assay: two
components in a single tablet.
1980s
Robotics: weighing; extractions; dilutions;
centrifugation
Automated injectors
Integration of areas (advanced LAS)/reliable raw data
files
Printed data files for notebook entry
Result: One Chemist- 30-40 samples per 11/2 days
Figure 5. Evolution ofa typical gas chromatographic assay: two
components in a single tablet.
integrated systems are the ultimate goal, it has been
found that, even if considered separately, operations can
be automated and made more efficient using ’distinct
systems’, rather then ’force’ a premature integration ot
systems that appear to do everything. In Schering-
Plough’s laboratories, the principle operations have been
segregated into various categories:
(1) Logging/scheduling of samples.
(2) Analysis: manipulations; instrumental analysis;
calculations.
(3) Data handling to effect formatted results.
(4) Tabulated presentations/reports/statistics.
(5) Productivity measurements: number of determi-
nations; project accountability; headcount
justification.
The following components meet most of the author’s
laboratory automation needs:
(a) Autosamplers: direct measurements, chromato-
graphic injections, dilutions, etc.
(b) Robotic systems: manipulations.
(c) Laboratory automation systems: chromatographic
integrations; calculations; raw/processed data files.
(d) Database management systems: LAS Interface;
stability data files; software to ’act on’ the database.
(e) Spread sheet: productivity assessment.
The payback for these is obvious. Scheduling is simplified
as is a readily available archive. One can more effectively
monitor and control sample backlog. Compliance issues
can be rapidly addressed regarding sample identification
and disposition among various laboratories, chemists and
notebooks. Analysis may be conducted with minimal
operator manipulations. Not only does this maximize
sample turnover, but it also minimizes the chance for
errors. Data handling is streamlined, with interim data
reports and trend analyses being carried out in a fraction
of the time formerly required. Regulatory quality reports
and tablets can be rapidly generated with minimal
transcription required. Finally, productivity measurements
can be generated on a monthly basis, if desired, which
trend laboratory workload, productivity and resource
needs and availability.
However, these paybacks are not without a price. These
systems require extensivevalidation and speci-
fic inspection criteria versus regulatory guidelines, which
constantly evolve. Additional calibration and preventive
maintenance are necessary, since malfunctions can be
subtle. General use in the laboratories requires additional
department SOPs and consensus agreement among supervisors,
which can create individual manager restrictions and
boundaries which are less than popular. Further, many
analyses need to be customized to facilitate automation.
Time studies and project loads need to be assessed, for
example is it more productive to limit automation to
sample preparation or should chromatographic injections
be included? Because these systems are in daily use, they
become taken for granted, leading to the potential forE. J. McGonigle Practical aspects of laboratory automation in pharmaceutical development
significant impact on laboratory productivity in the event
of computer malfunction or system failure. Finally, one must
guard against the impression that analyses are completed
when, in reality, results are unavailable due to the chemist
waiting for extensive print-outs and completion of
paperwork.
While these tradeoffs have to be considered, there can be
little doubt that automated systems benefit most labora-
tories when assessed with perspective versus day-to-day
needs. The use ofthree systems in the author’s Analytical
Research and Development Laboratories is discussed,
and the qualitative and quantitative conclusions that
have been drawn as to their contribution to the daily
operations are given. The systems are: LAS, robotics and
spreadsheet analysis. Overall, it is important to remem-
ber that payback can always be looked at in quantitative
terms. Increased productivity can result for better audit
trails and better guards against error, although the effort
can require more input. Every laboratory is sufficiently
unique to the extent that their experiences are often
different. Therefore, in some respects, the following
discussion is obvious with regard to specific brands of
equipment, it has been limited to the author’s experience
with systems and not specific brands.
Laboratory Automation System (LAS)
The author’s view of an LAS system is that it facilitates
chromatographic injections/integrations, calculations
and data presentations. From a regulatory point of view,
it reduces the subjectivity that the chemist adds to the
review of chromatographic baselines, and subsequent
decisions which he or she must make regarding various
integration parameters. The system will present the area
for integration versus proposed parameters, allowing the
chemist to take into account subtle, regional aberrations
in the tracing through the ability to amplify any specified
region of the chromatogram through scale expansion.
More importantly, the supervisor can review sample
tracings to verify conclusions drawn by the chemist. The
result is that integrations are both rapid and normalized
versus fixed criteria. Calculations can be rationalized.
New peaks, which might signify impurities and/or
degradation products, can be assessed and quantified.
Processed data files provide untranscribed records of
sample identification, calculated results and integration
parameters. Raw data files can be retained for review and
verification at some future date. From a practical point of
view, one cannot dispute the significance of the above,
regulatory advantages. The advantages require operator
input, but ensure quality data, an important but more
intangible contribution to productivity. To determine a
quantitative net effect, the time required to manually
complete a series of calculated results was monitored, for
a typical HPLC chromatographic analysis, and com-
pared to that required using the LAS system. The
protocol consisted ofan HPLC analysis of 18 samples ofa
dosage form containing an enantiomeric compound. The
comparison did not include sample manipulations
including chromatographic injections. We found the
overall time savings remains substantial despite the more
detailed review the chemist was afforded using LAS. The
assessment is as shown in table 1.
From the point of view of elapsed analysis time,
utilization of LAS/Data Analysis does not affect this
significantly since analysis time is chromatography-
driven (LAS amasses data with each chromatogram).
However, LAS allows analyses to continue off-hours.
Therefore, up to three times the number of samples can
be processed. A major advantage of all forms of
automation is the conduct of analysis off-hours. In the
author’s laboratories, 70-80% of all chromatographic
analyses are conducted in this fashion with the chemist,
ideally, devoting an eight hour work day to prepare
samples which require up to 16 hours ofchromatography
time. While this may seem self-evident, one has to
consider that were the sample load limited to, say, five
samples (10 determinations) it may not be worth
overloading a fully utilized LAS system for this work since
these analyses could possibly be efficiently completed
manually by a chemist in a single working day. Were
there a series ofsuch situations occurring simultaneously,
utilization of LAS could actually decrease productivity
(by slowing LAS response), with only the regulatory
advantages remaining the pivotal consideration. Power
system failures used to be a major limitation to LAS
systems but constant power sources have virtually
eliminated these problems and this equipment is really no
more limited than any other laboratory instrument.
Computer malfunction, or system failure, is potentially a
far more serious situation and must be weighed into the
commitment a laboratory makes regarding all laboratory
automation, particularly if integrated systems are used.
Robotics
While LAS has contributed to efficiency in chromato-
graphic analyses, robotics has significantly reduced
operator time in carrying out sample preparation. Early
versions of robotics (pre 1980s) were limited for the most
part to quality control laboratories dealing with high-
volume marketed products. The rigid/fixed configu-
rations of early robotic systems were not readily amen-
able to the changeover required for different products. In
addition, method development required several months,
in part, related to robotic programming. Highly trained
staff were necessary for dedicated commitment to utiliz-
ing the robot.
In R&D, two attributes in the nature ofthe workload play
a pivotal role determining the practicality of an invest-
Table 1. LAS compared with manual procedure.
Operator Operator
Activity manually LAS
Define/Draw baselines
Measure peak heights
Tabulate values
Calculations
Notebook completion
Total
1.7h 0-5h
l’7h 0"0h
0-5 h 0"0h
3"0 h 0"0 h
0"5 h 0"5 h
7-4 h 1"0 hE. J. McGonigle Practical aspects of laboratory automation in pharmaceutical development
ment in a robotic system. First, R&D projects evolve in
stages. Early in clinical trials, preliminary formulations/
doses are used. As the clincial program progresses,
additional doses are identified as are final product
images, which can be very different. For example,
capsules generally evolve into tablets of varying dosage
strengths and, perhaps a controlled or sustained release
dosage form is developed. To confound things further, it
is well known that only a small percentage of R&D
projects actually make it through rigid toxicology and
clinical programmes to become a successful product. A
project can be terminated at any time during develop-
ment such that it is difficult tojustify purchase ofa robotic
system for any individual project. Finally, a unique
attribute ofstability studies conducted in analyticalR&D
laboratories is that samples are not, generally, placed on
stability at the same time. They are manufactured,
sometimes months apart. In addition, new studies are
conceived, very often, as a outgrowth of success in the
clinic. New dosage strengths or the potential for a
controlled or sustained release dosage form are identified
in this fashion. Therefore, workload can not easily be
pooled to obtain maximum efficiency ofa robotic system.
Current robotic technology, however, has greatly
enhanced the flexibility of interchanging configuration
and method development time has been greatly reduced.
Today, it is not unreasonable to conceive ofusing a single
robotic system to facilitate 10-15 projects. Simplified
configurations and programming have allowed relatively
inexperienced staff to be adequately trained for an
analysis in as little as one day. Next to the flexibility of
interchanging components, the most significant improve-
ment has been in the introduction of programmes which
facilitate mixing ofdifferent strengths and dosage forms of
a single product. Sample weights and prescribed dilu-
tions can be stored in memory: printouts denote both
dosage form and dilution. The ability to correlate
’intended concentration’ with appropriate dilutions had
allowed samples of a compound to be analysed using the
same robotic method employed for defined dosage forms
in other matrices, for example for feed anlayses employed
in toxicology studies. System productivity software can
optimize robotic manipulations when a variety of steps
are used. Concurrent software allows ’non-robotic’ steps,
such as filtration and centrifugation, to proceed indepen-
dently. Programmes can be developed as canned systems,
which allow certain sample manipulations, like liquid/
solid extractions, to be utilized in common, one product
or another. Alternatively, one can modify programme
steps or string programmes together. All of these
relatively recent features have allowed methods to be
developed in days not weeks, using all laboratory staff,
not a specially trained few. The latter are still needed but
can be reserved for more sophisticated problems or for
preventative maintenance and calibration.
Method transfer is a stringent requirement for analytical
R&D laboratories. The principal goal, once stability has
been demonstrated and specifications developed, is to
transfer analytical methods, developed in our labora-
tories, to other potential testing sites which will be
required to use them to release new products and
continue marketed, product stability programmes.
Method transfer requires a strong interface with quality
control staff. Protocols need to be mutually agreeable.
Robotic and manual methods must be provided in
addition to validation reports which demonstrate both
are accurate and precise and statistically correlate.
Procedures must be written, step-by-step, and catalogued
in order to track revisions. System suitability require-
ments must encompass both the manual and robotic
versions. Logic diagrams must be provided along with
system security. Finally, statistical analysis criteria must
allow manual and robotic versions to be compared
between laboratories.
To demonstrate the effect these improvements have
contributed to enhanced feasibility for robotics in an
R&D environment, specific elements of a method deve-
lopment protocol were compared using manual and
robotic methods. Development times were tabulated for
single component developmental dosage forms. Both
capsule and tablet formulations were considered at
dosage strengths of 25 mg and 100 mg for both formula-
tions. The analytical method consisted of a liquid/solid
extraction, dilution and an isocratic HPLC determi-
nation: a ’dilute and shoot method’. A common require-
ment was the expenditure of 13 days (34% of total effort)
to develop and validate the HPLC system, an enantio-
meric assay (two centres; four isomers). This time would
have been required for either a manual or robotic method.
Sample preparation required three days (7% of total
effort). Validation of the manual component of the
method required 10 days (25% of total effort). Robotic
programming and validation required only three days
(7% and six days 15% ), respectively. Documenting the
methods, exclusive of validation reports required five
days (12% of total effort). Total method development
time amounted to 40 days for both manual and robotic
versions of this method, a reasonable time frame for the
manual method alone. This same procedure was further
evaluated by comparing actual operatator analysis times,
manual vs robotic versions. It should be noted that this
experiment was designed to include the effective contri-
bution of automated versus manual injections. The data
show that, manually, sample preparation elf 18 samples
(36 determinations) plus two standards required approxi-
mately 6"3 h of operator time, compared to just under
h employing the robot. Overall, conducting the analysis
using robotics to facilitate sample manipulations and
autoinjectors reduced the total analysis time from 12"7 h
to just under 4 h. Assessments of this type are necessary
to demonstate the practical utility of automation for a
given analysis. Efficiency may decrease when the number
of samples is reduced. However, practical utilization of
robotics is obviously dependent on the number of
manipulations required in sample preparation. For most
dilute and shoot methods, sample analyses requiring in
excess ofapproximately 20-25 injections effects optimum
productivity. In this particular example, the operator
would have ample time, in day one, to complete final
assay reports/notebook entries plus prepare samples for
the second day’s run. It is important to note that the
analysis continues after the chemist has left for the day
and, therefore, successful application was limited to a
shift operation. It should be apparent that this assess-
ment would have reached very different conclusions, were
the laboratory using two shifts (see tables 2 and 3).E. J. McGonigle Practical aspects of laboratory automation in pharmaceutical development
To give a very different point of view, the use of
automation in dissolution testing will be considered next.
Overall, it has b6en found that the gain in productivity is
optimal for large volume samples requiring shorter
dissolution run times. Therefore, in the author’s labora-
tories, robotics are best suited to dissolution testing of
immediate release dosage forms which require h run
times and testing of six individual tablets. Automated
testing of controlled or sustained release products has its
limitations.
(1) All-manual: preparation of all solvents; filling of
dissolution pots; sampling at desired intervals; spec-
trophotometric or chromatographic measurements;
calculations.
(2) Semi-automated: sampling at desired intervals; spec-
trophotometric or chromatographic measurements;
calculations
(3) Robotic: all steps exclusive of preparation of dissolu-
tion medium.
Dissolution testing is normally conducted in either of
three modes:
In a typical h dissolution test of six tablets (immediate
release), using four sample intervals, the data show the
following:
Table 2. Person-days requiredfor method development.
Product: single component- capsule and tablet
Dose: 25 mg and 100 mg per unit dose
Principle:. liquid/solution extraction; dilute/shoot; HPLC
Days % total
Activity required effort
Development LC system: Enantio- 13 34%
metric assay with two centres
(four isomers)
Sample preparation 3 7%
Validate manual method 10 25%
Robotic programming 3 7%
Robotic validation 6 15%
Document methods (Not validation 5 12%
reports)
Total 40 100%
Table 3. Comparison ofoperator times: robotic versus manualfor
typical stability analysis.
Assignment: 18 samples plus two standards
Activity Manual (h) Robotic (h)
Equipment set-up 0"25 0"25
Prep standards 0-50 0"50
Add samples 0-10 0" 10
Add solvent 1"00 0"00
Disint/diss samples 0"50 0"00
Add internal standard 2"00 0"00
Sample mixing 0"50 0-00
Centrifugation/setting 0" 10 0"00
Aliquoting 0" 10 0"00
Dilution/mixing 0"75 0"00
Fill LC vials 0"50 0"00
Subtotal 6"30 0"85
Prepare mobile phase 1-00 1"00
Equilibrate system 2"00 2"00
Injection 51 samples 3"40 0"00
(presumes 4 min chroma-
tography)
Total 12"70 3"85
Dissolution Number of runs/ Operator
mode day possible time
Manual 2 8 h
Semi-automated 3 6 h
Robotic 12 7.5 h
Measuring the cost outlay (operator and equipment), the
data show the following:
Operator/
Dissolution equipment Runs/year Total cost
mode cost optimal per run
Manual $64 M 400 $160.00
Semi-automated $92 M 600 $153.00
Robotic $200 M 2400 $83.00
It can be concluded that 2400 dissolution runs ofthis type
can achieve a saving of $185 000 in one year, assuring
rapid payback for the robot.
On the other hand, similar assessments for controlled or
sustained release products show that only for an ’8 h
product’ does robotics contribute measurably to produc-
tivity. In fact, for ’16 h and/or 24 h products’, there in no
particular cost saving associated with automating
dissolution.
Spreadsheet
All good laboratories develop a calendar year plan. These
are used by management to estimate resource utilization
for ongoing projects and to project resource needs to meet
goals for new projects. However, in R&D, priorities can
change rapidly. In addition, new projects can be initiated
during the course of a year when potential new drug
candidates are identified by the discovery laboratories.
Potential licensing candidates are under review con-
stantly, and can, very rapidly, become new projects. At
Schering, priorities are reviewed monthly by manage-
ment. Most often, for the analytical laboratories, a
decision to move a project to a lower level of priority has
very little impact once stability studies have been
initiated because this work can not be interrupted
without losing valuable data. As pointed out earlier,
adding even small projects has a dramatic impact on
analytical testing. As a consequence, unless a project is
cancelled, analytical workload tends to increase during
the course of a year, not decrease. As a general rule, theE. j. McGonigle Practical aspects of laboratory automation in pharmaceutical development
larger the analytical department, the more difficult it
becomes to credibly justify to management the point at
which additional workload can not be absorbed. Whole
tracking projects versus headcount utilization remains
important, this is effectively accomplished through time
cards and project codes. However, this is mostly ’retros-
pective’ and does not really capture the magnitude of
analytical testing which goes into a project. We have
found that an independent spreadsheet analysis, which
categorizes and counts the various kinds of analyses
which are carried out, presents a very credible overview of
headcount utilization and needs for management.
There is abundant availability of spreadsheet software
packages. Technology exists for computer-assisted inter-
facing between stability protocols and assay requests
using a Laboratory Information Management System
(LIMS). However, the author’s laboratory uses an
independent spreadsheet system. Laboratory managers
provide all input data which helps them to remain close to
those day-to-day operations. First, managers categorize
all analytical determinations carried out in their respect-
ive laboratories on a monthly basis. Many, if not most,
chemists independently summarize their activities daily:
the system simply requires they keep a written record of
this, with the total number of determinations, by
category, provided to their managers on a monthly basis.
Fourteen categories are utilized but, generally, a chemist
does not exceed one or two catagories on any given day.
Total determinations, by laboratory/category, are incor-
porated into spreadsheet formulas which then show
relationships between monthly/yearly available work
days and the number of available chemists. The data are
corrected for laboratory outages due to illness or open-
ings. For example the data show that, for the first eight
months in 1992, the author’s laboratories generated
approximately 162 000 determinations, averaging 953
determinations per working day and 10"9 determinations
per bench chemist per day. The spreadsheet presents
simple graphical summaries ofworkload distribution, by
category and laboratory, for management review. For
example, in this period, the data show that 20% of
laboratory efforts went into method development; 8"6%
to releasing clinical supplies; 3"8% to certifying reference
standards; 5% to instrument calibration and 16% to
screening ’candidate’ formulations. Summaries can be
focused on individual laboratories or the entire depart-
ment. With few exceptions, the laboratories are organized
such that different laboratories become involved as a
project progresses through clinical development. There-
fore, it can be identified quickly if more resources are
necessary because ’new chemical entities’ are entering
development, as opposed to those projects which are
consuming resources related to: testing to support
proposed ’line extensions’, technical support to manu-
facturing etc. The system is very useful in documenting
the utilization of resources and, overall, maintaining
the credibility of the analytical laboratory (see tables 4
and 5).
Table 4. 1992 workload summary.
Source Jan Feb Mar Total
PSRs 228 899 298
Methods development 3 344 3 688 3 909
PMRs 085 549 521
Instrument calibration 328 256 028
Miscellaneous 630 594 255
PRNs 9 011 7 660 8 421
QC support 105 57 233
Raw material 855 263 275
Special PRNs 2 361 2 778 2 681
Toxicology support 249 342 284
Special services 109 57 129
Standards 829 310 968
Contract laboratory
data 108 408
Cleaning validations 150 79
Total 22 284 208 922
7 166
32 686
6 592
8 909
9 473
52 842
876
5 844
26 367
638
827
6 362
276 3 599
160 376
22 152 161 958
* Contract labatory not included
Table 5. 1992 Workload summary.
Jan Feb Mar Total
Available work
days 22 19
Total deter- 22 284 20 892
minations
Determin-
ations/day 013 100
Total chemists 88"8 88"8
Determinations 11.41 12"93
per man day
22 170
22 152 161 958
007 953
89"8 87"6
11"22 10"88
Summary
Automation in the analytical R&D laboratory can be
productive with tangible payback. While certainly opti-
mal, it is not necessary to fully integrate various systems
to achieve this. In fact, there is a certain vulnerability
associated with system integration although I believe
developments’ future will minimize concerns in this
regard. Computers have been the principal factor in all of
these accomplishments. While this discussion has been
limited to only a few applications these examples
demonstrate the importance of assessing individual
laboratory needs carefully before making capital and
resource commitments to automation. This should
include a plan to capture ’payback versus payout’ once
the systems are in place.
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